News and Comments

AstraZeneca Selects Mirati Therapeutics Drug For Its cancer Immunotherapy Combination

  Thursday, August 06, 2015

In The NEWS More...

NANTKWEST INC. A Novel Breathtaking Immunotherapy For Cancer?

  Monday, August 03, 2015

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day seemed confident that the stock would surge. As a matter of fact, the stock did surge.    More...

EXELEXIS: The Importance Of The Public Offering. XOMA: What Should We Do Now?

  Thursday, July 23, 2015

Why the financing through a secondary public offering was a must for Exelixis?  More...

AMGN: Rapatha Approved In Europe

  Tuesday, July 21, 2015

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol More...

Anacor Pharmaceuticals Ointment for Atopic Dermatitis Passes the Tests. Why is this Great News?

  Tuesday, July 14, 2015

An Effective Non-Steroid Atopic Dermatitis Ointment More...

Trovagine: Overcoming Challenges In Cancer Immunotherapy

  Wednesday, July 08, 2015

After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer immunotherapy), novel approaches based on new discoveries have finally demonstrated they can do the hard job. These treatments, however, are facing challenges, which must be dealt with. Will Trovagine (TROV) succeed in dealing with the challenges?  More...

Unearthing Dynavax Treasures has Nothing To Do with Greece Troubles

  Monday, June 29, 2015


Biocryst: A Major Game Changing Agreement

  Monday, June 22, 2015

On Thursday June 18, we posted an article in “Today’s Highlights” section in the Prohost Website about an important agreement Biocryst Pharmaceuticals (BCRX) signed with CSL We expect the agreement to contribute a great deal into bringing effective treatments of disabling chronic progressive diseases and life-threatening acute diseases to the global market   More...

Immunogen: Defeating Advanced Ovarian Cancer And Other Malignancies

  Tuesday, June 02, 2015

- Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. More...

Xoma: Phase 3 EYEGUARD-B Trial is Good News For Gevokizumab

  Wednesday, May 27, 2015

Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab for Behcet’s uveitis. The study, which is sponsored by Xoma’s development partner Servier, reached its target exacerbation event as specified in the study design.  More...

Recent Postings



Ionis (IONS) Valeant Pharmaceuticals International (VRX) Micromet (MITI) Jazz Pharmaceuticals (JAZZ) Pluristem (PSTI) HALOZYME (HALO) Intermune (ITMN) SUNESIS PHARMACEUTICALS (SNSS) Sanofi (SNA) JUNO (JUNO) Editas (EDIT) Incyte (INCY) Sanofi-Aventis (SAN) BIOMARIN (BMRN) Intercept (ICPT) AERIE PHARMACEUTICALS Roche (RHHBY) Telaprevir Rapamune Biogen Idec (BIIB) Abbott Laboratories (ABT) Illumina (ILMN) ABBVIE (ABBV) Idenix (IDIX) KERYX (KERX) Exelixis (EXEL) Cytokinetics (CYTK) NANTKWEST (NK) Onyx (ONXX) ZALTRAP™ Seattle Genetics (SGEN) Auspex (ASPX) Amgen (AMGN) Theravance Bio Pharma (TBPH) Multiple Myeloma Trastuzumab-DM1 Mirati Therapeutics (MRTX) Zerenex Ariad (ARIA) ImmunoGen (IMGN) Tysabri Benlysta (belimumab) TOKAI (TKAOI) SYNTA (SNTA) VANDA (VNDA) Elan (ELN) galapagos (GLPG) Theravance (THRX) Sarepta (SRPT) Velcade (bortezomib) Genentech Anadys (ANDS) Endometrial Cancer GUARDIAN HEALTH Regeneron (REGN) Xoma (XOMA) Sequenom (SQNM) Biocryst (BCRX) ACADIA (ACAD) Vertex (VRTX) IDERA (IDRA) Vitae Pharmaceuticals (VTAE) Sangamo (SGMO) Bristol-Myers Squibb (BMY) ISIS (ISIS) Aimmune Therapeutics (AIMT) Agenus (AGEN Prolor Biotech (PBTH) Prosensa (RNA) PTC Therapeutics (PTCT) Human Longevity (HLI) Dynavax (DVAX) Herceptin NEKTAR (NKTR)) ADVENTRIX (ANX) ARCA (ABIO) Dendreon (DNDN) Human Genome Sciences (HGSI) Roche (ROCHE) Alder Biopharmaceuticals (ALDR) Agenus (AGEN) C4 Therapeutics Gilead (GILD) Ziofpharm (ZIOP) REGULUS (RGLS) Array Pharmaceuticals (ARRY) Sanofi (SNY) OSI (OSIP) Revlimid (lenolidamide) KITE (KITE) Anacor (ANAC) Alnylam (ALNY) Inovio (INO) GlaxoSmithKline (GSK) Galena (GALE) SERES THERAPEUTICS (MCRB) Intrexon (XON) Merck (MRK) Ridaforolimus CompuGen (CGEN) RenenxBio (RGNX)